Drug intelligence / Profile preview

BRIXELLE-ONCO

Development stage: Preclinical
Lead developer: Bilix
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

BRIXELLE-ONCO is a preclinical-stage drug delivery platform developed by Bilix. It utilizes a PEGylated bilirubin nanoparticle system designed for intravenous administration to treat various forms of cancer. Bilirubin, a natural antioxidant and anti-inflammatory molecule, is engineered into nanoparticles to improve solubility, stability, and targeted delivery of therapeutic agents. While the specific molecular targets and payloads for BRIXELLE-ONCO remain undisclosed, the platform leverages the inherent biological properties of bilirubin to potentially enhance the efficacy and safety of oncology treatments.

Other names: PEGylated Bilirubin nanoparticle drug delivery system

Beyond the preview

Go deeper on BRIXELLE-ONCO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRIXELLE-ONCO.

Explore the full profile